Beta Drugs (NSE:BETA) ROCE % : 29.21% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Beta Drugs ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Beta Drugs's annualized ROCE % for the quarter that ended in Mar. 2024 was 29.21%.

Beta Drugs ROCE % Historical Data

The historical data trend for Beta Drugs's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beta Drugs ROCE % Chart

Beta Drugs Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

23.65

23.49

37.38

35.59

33.84

Beta Drugs Semi-Annual Data
	Mar13	Mar14	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
ROCE %	Get a 7-Day Free Trial														37.14	38.96	33.14	38.64	29.21

Beta Drugs ROCE % Calculation

Beta Drugs's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	515.742	/	( ( (1984.215 - 630.159)	+	(2540.986 - 846.689) )	/ 2 )
	=	515.742	/	( (1354.056	+	1694.297)	/ 2 )
	=	515.742	/	1524.1765
	=	33.84 %

Beta Drugs's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Sep. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Sep. 2023 )		(Q: Mar. 2024 )
	=	472.42	/	( ( (2372.669 - 832.805)	+	(2540.986 - 846.689) )	/ 2 )
	=	472.42	/	( ( 1539.864	+	1694.297 )	/ 2 )
	=	472.42	/	1617.0805
	=	29.21 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2024) EBIT data.

Beta Drugs (NSE:BETA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Beta Drugs ROCE % Related Terms

Thank you for viewing the detailed overview of Beta Drugs's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Beta Drugs (NSE:BETA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beta Drugs Ltd (NSE:BETA) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114

Website

https://www.betadrugslimited.com

Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports it to other countries of which key revenue is derived from the sales made in India.

Beta Drugs (NSE:BETA) Headlines

No Headlines